Development | Vaccine | Against Rotavirus
Against Rotavirus
The vaccine is based on a recombinant protein. We increased its valency, ensuring immunity against rotavirus groups A, B, and C. The design incorporates epitopes from VP6 and VP8 proteins of these rotavirus groups. Upon exposure to rotavirus A, B, or C, the induced immunity prevents infection or ensures a mild course of the disease.
The vaccine has both preventive and therapeutic effects. Its safety is ensured by using a recombinant protein as the active ingredient, eliminating risks associated with inactivated virus administration.
Against Rotavirus
The vaccine is based on a recombinant protein. We increased its valency, ensuring immunity against rotavirus groups A, B, and C. The design incorporates epitopes from VP6 and VP8 proteins of these rotavirus groups. Upon exposure to rotavirus A, B, or C, the induced immunity prevents infection or ensures a mild course of the disease.
The vaccine has both preventive and therapeutic effects. Its safety is ensured by using a recombinant protein as the active ingredient, eliminating risks associated with inactivated virus administration.
Patents for Inventions
Application No. 2539913 – Vaccine for Prevention and Treatment of Rotavirus Infection Containing a Hybrid Protein as Active Agent (Variants)
Application No. 031404 – Vaccine for Prevention and Treatment of Rotavirus Infection Containing a Hybrid Protein as Active Agent (Variants)
Awards for Development
Archimedes 2017 – Diploma, Gold Medal
Leave your request, and we will contact you.
Would you like us to develop a custom drug?
Сообщение об успешной отправке!
Phone:
Email:
